The treatment of cancer remains one of the most prolific challenges of our generation. With new cancer cases predicted to rise to over 35 million globally by 2050, the demand for new and innovative treatment options has never been greater.

In the past decade, oncology research has increasingly focused on personalized treatments, designed to target cancerous cells, improving safety and survival rates, as well as quality of life for the patient.

However, the rapid advancements in cancer treatment have come accompanied by new challenges, including stringent regulatory compliance and the need for specialized technologies and laboratory testing.

Early engagement for optimal results

Laboratory testing starts with selecting the most appropriate assay.  Our team of Research & Development experts leverage their experience and knowledge to provide insight into the most suitable biomarkers and assays for your study.

Design, validation and delivery of assays to regulatory standards

Cerba Research has the technology platforms, instruments and experts to execute a range of oncology testing including Flow Cytometry, Histopathology, Molecular Testing and Next Generation Sequencing.

Laboratory services for all phases

Laboratory services at every stage of the development process, from pre-clinical to phase IV, enables smooth transition between phases with continuity of assay availability and reducing the risk of delays.

Central Laboratory set-up timelines that meet study requirements

Proven Central Laboratory study set-up timelines, ranging from 6 to 8 weeks, depending on the complexity of the study.

Global deployment of assays

Assays are globally accessible, with our proven expertise in method/technology transfer and compliance with regional and local regulatory standards.

We have had ~200 oncology trials since 2018 and growing. We perform specialty testing in ~75% of cases within those trials. Specifically, we can perform immunohistochemistry (IHC), flow cytometry (FCM), and/or NGS, amongst other innovative techniques. We can also perform any routine testing (aka safety testing), such as, but not limited to, coagulation, biochemistry, urinalysis, pregnancy test, COVID testing and serology, which are essential for any oncology trial and patient inclusion / exclusion criteria. We can also help design and validate specialty-based assays that account for the complex tumor microenvironment of both solid tumors and hematological malignancies.

Cerba Research has supported biopharma and pharmaceutical companies in developing oncology therapies. Our heritage in specialty labs and our experience in central lab services enable us to develop research techniques to underpin the next generation of clinical trials. A new kind of research where diagnostics are driven by clinical data and insights, supported by specific therapeutic expertise.